Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin
Eisuke Murakami(Hiroshima University), Kazuaki Chayama(RIKEN Center for Integrative Medical Sciences), Michio Imamura(Hiroshima University), Masataka Tsuge(Hiroshima University), Tomokazu Kawaoka(Hiroshima University), Hiromi Abe(Hiroshima University), Hiroshi Aikata(Hiroshima Prefectural Hospital), Daiki Miki(Hiroshima University), Atsushi Ono(Hiroshima University), Hirotaka Matsui(Hiroshima University), Nobuhiko Hiraga(RIKEN Center for Integrative Medical Sciences), Akinori Kanai(Frontier Medical College), Fiona McPhee(Bristol-Myers Squibb (United States)), Shoichi Takahashi(Hiroshima University), Hidenori Ochi(Hiroshima University), Yoji Honda(Hiroshima University), Toshiya Inaba(Hiroshima University), Keiichi Kosaka(Hiroshima University), C. Nelson Hayes(Hiroshima University)
Cited by 18
Related Papers
A proposed system for the nomenclature of hepatitis C viral genotypes
|Hepatology|1994|1k
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
|Hepatology|2015|689